|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: F11 |
Gene summary for F11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | F11 | Gene ID | 2160 |
| Gene name | coagulation factor XI | |
| Gene Alias | FXI | |
| Cytomap | 4q35.2 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | P03951 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2160 | F11 | NAFLD1 | Human | Liver | NAFLD | 3.39e-09 | 8.29e-01 | -0.04 |
| 2160 | F11 | S41 | Human | Liver | Cirrhotic | 2.97e-02 | 3.45e-01 | -0.0343 |
| 2160 | F11 | S43 | Human | Liver | Cirrhotic | 9.43e-06 | -1.35e-01 | -0.0187 |
| 2160 | F11 | HCC1_Meng | Human | Liver | HCC | 1.63e-19 | -1.91e-01 | 0.0246 |
| 2160 | F11 | HCC2_Meng | Human | Liver | HCC | 1.05e-09 | -2.27e-01 | 0.0107 |
| 2160 | F11 | cirrhotic2 | Human | Liver | Cirrhotic | 3.54e-03 | -1.78e-01 | 0.0201 |
| 2160 | F11 | HCC2 | Human | Liver | HCC | 6.20e-06 | 3.36e+00 | 0.5341 |
| 2160 | F11 | Pt14.d | Human | Liver | HCC | 4.93e-02 | -1.87e-01 | 0.0143 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00430879 | Prostate | BPH | regulation of GTPase activity | 88/3107 | 348/18723 | 2.04e-05 | 2.49e-04 | 88 |
| GO:005134616 | Prostate | BPH | negative regulation of hydrolase activity | 94/3107 | 379/18723 | 2.46e-05 | 2.94e-04 | 94 |
| GO:00510568 | Prostate | BPH | regulation of small GTPase mediated signal transduction | 78/3107 | 302/18723 | 2.69e-05 | 3.16e-04 | 78 |
| GO:01501058 | Prostate | BPH | protein localization to cell-cell junction | 12/3107 | 21/18723 | 2.85e-05 | 3.32e-04 | 12 |
| GO:001063916 | Prostate | BPH | negative regulation of organelle organization | 87/3107 | 348/18723 | 3.56e-05 | 3.90e-04 | 87 |
| GO:00465787 | Prostate | BPH | regulation of Ras protein signal transduction | 53/3107 | 189/18723 | 5.08e-05 | 5.24e-04 | 53 |
| GO:00356338 | Prostate | BPH | maintenance of blood-brain barrier | 16/3107 | 35/18723 | 5.35e-05 | 5.47e-04 | 16 |
| GO:000931414 | Prostate | BPH | response to radiation | 105/3107 | 456/18723 | 2.07e-04 | 1.70e-03 | 105 |
| GO:004329710 | Prostate | BPH | apical junction assembly | 26/3107 | 78/18723 | 2.24e-04 | 1.80e-03 | 26 |
| GO:00514976 | Prostate | BPH | negative regulation of stress fiber assembly | 14/3107 | 32/18723 | 2.77e-04 | 2.16e-03 | 14 |
| GO:005087817 | Prostate | BPH | regulation of body fluid levels | 89/3107 | 379/18723 | 3.08e-04 | 2.37e-03 | 89 |
| GO:007052716 | Prostate | BPH | platelet aggregation | 23/3107 | 67/18723 | 3.12e-04 | 2.39e-03 | 23 |
| GO:00072668 | Prostate | BPH | Rho protein signal transduction | 39/3107 | 137/18723 | 3.37e-04 | 2.53e-03 | 39 |
| GO:00712604 | Prostate | BPH | cellular response to mechanical stimulus | 26/3107 | 81/18723 | 4.39e-04 | 3.16e-03 | 26 |
| GO:00096129 | Prostate | BPH | response to mechanical stimulus | 55/3107 | 216/18723 | 5.61e-04 | 3.91e-03 | 55 |
| GO:00905597 | Prostate | BPH | regulation of membrane permeability | 25/3107 | 78/18723 | 5.74e-04 | 3.99e-03 | 25 |
| GO:000715910 | Prostate | BPH | leukocyte cell-cell adhesion | 86/3107 | 371/18723 | 5.95e-04 | 4.11e-03 | 86 |
| GO:00322326 | Prostate | BPH | negative regulation of actin filament bundle assembly | 14/3107 | 35/18723 | 8.33e-04 | 5.41e-03 | 14 |
| GO:01201939 | Prostate | BPH | tight junction organization | 25/3107 | 80/18723 | 8.72e-04 | 5.62e-03 | 25 |
| GO:20002495 | Prostate | BPH | regulation of actin cytoskeleton reorganization | 15/3107 | 39/18723 | 8.91e-04 | 5.72e-03 | 15 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
| hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
| hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| F11R | F11R | F11R_F11R | JAM | Breast | ADJ |
| JAM2 | F11R | JAM2_F11R | JAM | Breast | ADJ |
| JAM3 | F11R | JAM3_F11R | JAM | Breast | ADJ |
| F11R | F11R | F11R_F11R | JAM | Breast | DCIS |
| JAM2 | F11R | JAM2_F11R | JAM | Breast | DCIS |
| JAM3 | F11R | JAM3_F11R | JAM | Breast | DCIS |
| F11R | F11R | F11R_F11R | JAM | Breast | IDC |
| F11R | F11R | F11R_F11R | JAM | Breast | Precancer |
| F11R | F11R | F11R_F11R | JAM | Cervix | ADJ |
| JAM2 | F11R | JAM2_F11R | JAM | Cervix | ADJ |
| F11R | F11R | F11R_F11R | JAM | Cervix | CC |
| JAM2 | F11R | JAM2_F11R | JAM | Cervix | CC |
| JAM3 | F11R | JAM3_F11R | JAM | Cervix | CC |
| F11R | F11R | F11R_F11R | JAM | Cervix | Precancer |
| JAM2 | F11R | JAM2_F11R | JAM | Cervix | Precancer |
| JAM3 | F11R | JAM3_F11R | JAM | Cervix | Precancer |
| F11R | F11R | F11R_F11R | JAM | CRC | AD |
| JAM2 | F11R | JAM2_F11R | JAM | CRC | AD |
| JAM3 | F11R | JAM3_F11R | JAM | CRC | AD |
| F11R | F11R | F11R_F11R | JAM | CRC | ADJ |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| F11 | SNV | Missense_Mutation | rs866758594 | c.1565G>A | p.Arg522Lys | p.R522K | P03951 | protein_coding | tolerated(0.42) | benign(0.125) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| F11 | SNV | Missense_Mutation | c.1597N>A | p.Gln533Lys | p.Q533K | P03951 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| F11 | SNV | Missense_Mutation | rs374606272 | c.550N>A | p.Val184Met | p.V184M | P03951 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| F11 | deletion | Frame_Shift_Del | novel | c.1343delN | p.Leu449Ter | p.L449* | P03951 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| F11 | SNV | Missense_Mutation | rs763496524 | c.802N>T | p.Arg268Cys | p.R268C | P03951 | protein_coding | tolerated(0.18) | probably_damaging(0.967) | TCGA-EK-A3GN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| F11 | SNV | Missense_Mutation | novel | c.673N>T | p.Val225Phe | p.V225F | P03951 | protein_coding | tolerated(0.08) | probably_damaging(0.993) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| F11 | SNV | Missense_Mutation | c.1641N>C | p.Lys547Asn | p.K547N | P03951 | protein_coding | tolerated(0.21) | benign(0.044) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| F11 | SNV | Missense_Mutation | c.760C>A | p.Leu254Ile | p.L254I | P03951 | protein_coding | deleterious(0.05) | possibly_damaging(0.795) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| F11 | SNV | Missense_Mutation | c.1003N>A | p.Ala335Thr | p.A335T | P03951 | protein_coding | tolerated(0.68) | benign(0.054) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| F11 | SNV | Missense_Mutation | c.913N>A | p.Glu305Lys | p.E305K | P03951 | protein_coding | deleterious(0.02) | benign(0.235) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | ANTITHROMBIN | |||
| 2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | THROMBIN | THROMBIN | 9787166 | |
| 2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | DEXTRAN SULFATE | 12968031 | ||
| 2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | hormonal contraceptives for systemic use | 28750087 | ||
| 2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | EP-7041 | |||
| 2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | ISIS-FXIRX | |||
| 2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 178103163 | ||
| 2160 | F11 | DRUGGABLE GENOME, PROTEASE, ENZYME | SULFATED PENTAGALLOYLGLUCOSIDE | SULFATED PENTAGALLOYLGLUCOSIDE | 23316863 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |